BioSpace News Archive

Salarius Pharmaceuticals, Inc. announced that it has closed its previously announced private placement for the issuance and sale of an aggregate of 3,636,364 shares of its common stock, Series A-1 warrants to purchase up to an aggregate of 3,636,364 shares of common stock and Series A-2 warrants to purchase up to an aggregate of 3,636,364 shares of common stock at a purchase price of $1.65 per share and accompanying warrants, priced at-the-market under Nasdaq rules.

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the three months ended March 31, 2023.

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”) today reported its financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.

Quest Diagnostics, the world’s leading provider of diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share, payable on July 25, 2023 to shareholders of record of Quest Diagnostics common stock on July 11, 2023.

Waters™ Corporation announced it has completed its acquisition of Wyatt Technology, a pioneer and well-recognized leader in innovative light scattering and field-flow fractionation instruments, software, accessories, and services.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Billy Dunn, M.D., to its Board of Directors.

ANI Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the Company”), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023.

Editas Medicine, Inc., a clinical-stage genome editing company, announced the appointment of Erick J. Lucera as Executive Vice President and Chief Financial Officer, effective May 17, 2023.

BELLUS Health Inc. announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting of shareholders of BELLUS on June 16, 2023.